Ajinomoto Of Japan Buys Rights To P&G Osteo Drug For $210 Million
This article was originally published in PharmAsia News
Executive Summary
Japan's Ajinomoto has agreed to pay $210 million for the rights to an osteoporosis drug from U.S.-based Procter & Gamble. The drug involved is P&G's Actonel (risedronate). With the agreement, Ajinomoto gets to take the drug from the research stage through marketing. While P&G phases out of the pharmaceutical business, Ajinomoto is moving into it, an expansion beyond its basic business of making seasonings. Takeda Pharmaceutical also makes risedronate and markets it in Japan as Benet. (Click here for more